The earnings miss and widening net loss reinforce the bearish case for AZTR, especially given the limited cash runway. Traders should watch for the Q3 2026 ATR-COSF human study start and Q4 2026 ATR-04 topline data as potential catalysts, but the near-term risk of dilutive financing remains high.
Price Chart
Executive Summary
Azitra reported Q2 2026 EPS of -$0.17, a miss vs consensus of -$0.23, with net loss widening to $3.3M from $2.9M YoY. The clinical-stage biopharma highlighted preclinical data for its ATR-COSF cosmetic program and continued enrollment in its ATR-04 Phase 1/2 trial, but paused its ATR-12 Netherton Syndrome study to conserve cash. With only $6.7M in cash and a $2M market cap, the earnings miss and cash burn rate are the primary concerns for traders.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.17 missed consensus of -$0.23.
- Net loss widened to $3.3M from $2.9M in Q2 2025.
- Cash and cash equivalents stood at $6.7M as of June 30, 2026.
- Company paused enrollment in the ATR-12 Phase 1b Netherton Syndrome trial to focus on higher-priority programs.
- ATR-COSF preclinical data announced; human cosmetic study planned for Q3 2026.
- ATR-04 Phase 1/2 trial for EGFR inhibitor-associated rash continues; topline data from first cohort expected Q4 2026.
Financial Impact
EPS miss of -$0.17 vs -$0.23 consensus; net loss increased 15.9% YoY to $3.3M; cash burn rate of ~$3.3M/quarter implies ~6 months runway.
Risk Factors
- Cash runway of ~6 months at current burn rate, high risk of dilutive equity offering.
- Clinical-stage pipeline with no approved products; ATR-12 trial pause signals capital constraints.
- EPS miss and widening losses indicate deteriorating financial health.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302850148 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.04 | awaiting T+1 | — | $1.53 (+47.12%) |
Oct 22, 2026 4d ago | 8-K | $0.0715 $0.1530 | ▲ +113.99% | ▲ +113.28% | $1.53 (+2039.86%) |
Oct 1, 2026 26d ago | 8-K | $0.1285 $0.1320 | ▲ +2.72% | ▲ +1.98% | $1.53 (+1090.66%) |
Aug 21, 2026 9w ago | 8-K | $0.1328 $0.1504 | ▲ +13.25% | ▲ +13.55% | $1.53 (+1052.11%) |
Aug 12, 2026 10w ago | Press Release | $0.1400 $0.1393 | ▲ +0.50% | ▲ +0.30% | $1.53 (−992.86%) |
Jun 17, 2026 18w ago | 8-K | $0.2030 $0.1717 | ▼ −15.42% | ▼ −16.20% | $1.53 (+653.69%) |
Jun 3, 2026 20w ago | EFFECT | $0.2240 $0.2180 | ▲ +2.68% | ▲ +3.08% | $1.53 (−583.04%) |
May 21, 2026 22w ago | S-1 | $0.2040 $0.2100 | ▼ −2.94% | ▼ −2.36% | $1.53 (−650.00%) |
Mar 5, 2026 33w ago | 8-K | $0.1800 $0.2030 | ▲ +12.78% | ▲ +11.93% | $1.53 (+750.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers